As shown in Table 4, higher SPARC methylation levels were significantly associated with a higher mortality risk both in all NSCLC patients (HR = 1.46; 95% CI: 1.07–2.00; p = 0.018) and in SqCC patients (HR = 2.04; 95% CI: 1.21–3.45; p = 0.008). This evidence concerns the gene SPARC and non-small cell lung carcinoma.